Circulating Cell-Free DNA as Inflammatory Marker in Egyptian Psoriasis Patients

Haneya AA Anani,1 Amany M Tawfeik,1 Soheir S Maklad,1 Abeer M Kamel,2 Enas E El-Said,3 Asmaa S Farag2 1Departments of Microbiology and Immunology, Faculty of Medicine for Girls, Al-Azhar University, Cairo, Egypt; 2Dermatology Department, Faculty of Medicine for Girls, Al-Azhar University, Cairo, Egy...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Anani HAA, Tawfeik AM, Maklad SS, Kamel AM, El-Said EE, Farag AS
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2020
Materias:	circulating cell free dna psoriasis severity index c- reactive protein psoriasis therapy. Dermatology RL1-803
Acceso en línea:	https://doaj.org/article/f6dcf878d8414c65acd84e901c4972f9
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:f6dcf878d8414c65acd84e901c4972f9
record_format	dspace
spelling	oai:doaj.org-article:f6dcf878d8414c65acd84e901c4972f92021-12-02T10:37:03ZCirculating Cell-Free DNA as Inflammatory Marker in Egyptian Psoriasis Patients2230-326Xhttps://doaj.org/article/f6dcf878d8414c65acd84e901c4972f92020-05-01T00:00:00Zhttps://www.dovepress.com/circulating-cell-free-dna-as-inflammatory-marker-in-egyptian-psoriasis-peer-reviewed-article-PTThttps://doaj.org/toc/2230-326XHaneya AA Anani,1 Amany M Tawfeik,1 Soheir S Maklad,1 Abeer M Kamel,2 Enas E El-Said,3 Asmaa S Farag2 1Departments of Microbiology and Immunology, Faculty of Medicine for Girls, Al-Azhar University, Cairo, Egypt; 2Dermatology Department, Faculty of Medicine for Girls, Al-Azhar University, Cairo, Egypt; 3Clinical Pathology Department, Faculty of Medicine for Girls, Al-Azhar University, Cairo, EgyptCorrespondence: Haneya AA Anani Email haneya.amr2008@yahoo.comBackground: Cell lesion and apoptosis with release of cell-free DNA (CFD) in circulation are associated with chronic inflammation of psoriasis.Objective: The objective of this study was to determine the CFD concentrations in sera of patients with psoriasis, to assess its relationship with disease severity as defined by Psoriasis Area Severity Index (PASI) and other inflammatory biomarkers (C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR)) levels, and to monitor the efficacy of treatment.Patients and Methods: Thirty adult patients with different types of psoriasis (25 vulgaris; 10 mild, 15 moderate and 5 erythroderma; severe) were evaluated during the exacerbation phase of the disease, before starting (T0) and after 12 weeks (T12) of treatment with topical therapy for mild cases, narrowband-ultraviolet light B (NB-UVB) for moderate cases and methotrexate for severe cases. Twenty healthy controls were also involved in the study. The concentrations of CFD in sera were measured before and after treatment by quantitative real time PCR (qPCR) using primers of the human β-globin gene.Results: At T0, all patients presented significant higher levels of ESR (P=0.05) and CFD (P=0.001) compared with controls. Highly significant elevations of all parameters were observed in severe disease (erythroderma) compared to mild/moderate disease (vulgaris). Methotrexate treatment induced highly significant reductions in all inflammatory markers including CFD (P= 0.042) while topical and UV irradiation therapies had no effects. CFD concentrations showed positive correlations with both PASI (r=0.422, P=0.020) and ESR (r=0.321, P=0.023) only before the start of treatment.Conclusion: The level of circulating CFD could be used to monitor psoriasis severity. However, its level cannot be stated for the treatment, except in severe erythrodermic patients upon successful treatment with methotrexate. We recommend validation of a convenient and accurate DNA assay applied directly to biological samples which does not require prior DNA extraction and amplification.Keywords: circulating cell-free DNA, Psoriasis Severity Index, C-reactive protein, psoriasis therapyAnani HAATawfeik AMMaklad SSKamel AMEl-Said EEFarag ASDove Medical Pressarticlecirculating cell free dnapsoriasis severity indexc- reactive proteinpsoriasis therapy.DermatologyRL1-803ENPsoriasis: Targets and Therapy, Vol Volume 10, Pp 13-21 (2020)
institution	DOAJ
collection	DOAJ
language	EN
topic	circulating cell free dna psoriasis severity index c- reactive protein psoriasis therapy. Dermatology RL1-803
spellingShingle	circulating cell free dna psoriasis severity index c- reactive protein psoriasis therapy. Dermatology RL1-803 Anani HAA Tawfeik AM Maklad SS Kamel AM El-Said EE Farag AS Circulating Cell-Free DNA as Inflammatory Marker in Egyptian Psoriasis Patients
description	Haneya AA Anani,1 Amany M Tawfeik,1 Soheir S Maklad,1 Abeer M Kamel,2 Enas E El-Said,3 Asmaa S Farag2 1Departments of Microbiology and Immunology, Faculty of Medicine for Girls, Al-Azhar University, Cairo, Egypt; 2Dermatology Department, Faculty of Medicine for Girls, Al-Azhar University, Cairo, Egypt; 3Clinical Pathology Department, Faculty of Medicine for Girls, Al-Azhar University, Cairo, EgyptCorrespondence: Haneya AA Anani Email haneya.amr2008@yahoo.comBackground: Cell lesion and apoptosis with release of cell-free DNA (CFD) in circulation are associated with chronic inflammation of psoriasis.Objective: The objective of this study was to determine the CFD concentrations in sera of patients with psoriasis, to assess its relationship with disease severity as defined by Psoriasis Area Severity Index (PASI) and other inflammatory biomarkers (C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR)) levels, and to monitor the efficacy of treatment.Patients and Methods: Thirty adult patients with different types of psoriasis (25 vulgaris; 10 mild, 15 moderate and 5 erythroderma; severe) were evaluated during the exacerbation phase of the disease, before starting (T0) and after 12 weeks (T12) of treatment with topical therapy for mild cases, narrowband-ultraviolet light B (NB-UVB) for moderate cases and methotrexate for severe cases. Twenty healthy controls were also involved in the study. The concentrations of CFD in sera were measured before and after treatment by quantitative real time PCR (qPCR) using primers of the human β-globin gene.Results: At T0, all patients presented significant higher levels of ESR (P=0.05) and CFD (P=0.001) compared with controls. Highly significant elevations of all parameters were observed in severe disease (erythroderma) compared to mild/moderate disease (vulgaris). Methotrexate treatment induced highly significant reductions in all inflammatory markers including CFD (P= 0.042) while topical and UV irradiation therapies had no effects. CFD concentrations showed positive correlations with both PASI (r=0.422, P=0.020) and ESR (r=0.321, P=0.023) only before the start of treatment.Conclusion: The level of circulating CFD could be used to monitor psoriasis severity. However, its level cannot be stated for the treatment, except in severe erythrodermic patients upon successful treatment with methotrexate. We recommend validation of a convenient and accurate DNA assay applied directly to biological samples which does not require prior DNA extraction and amplification.Keywords: circulating cell-free DNA, Psoriasis Severity Index, C-reactive protein, psoriasis therapy
format	article
author	Anani HAA Tawfeik AM Maklad SS Kamel AM El-Said EE Farag AS
author_facet	Anani HAA Tawfeik AM Maklad SS Kamel AM El-Said EE Farag AS
author_sort	Anani HAA
title	Circulating Cell-Free DNA as Inflammatory Marker in Egyptian Psoriasis Patients
title_short	Circulating Cell-Free DNA as Inflammatory Marker in Egyptian Psoriasis Patients
title_full	Circulating Cell-Free DNA as Inflammatory Marker in Egyptian Psoriasis Patients
title_fullStr	Circulating Cell-Free DNA as Inflammatory Marker in Egyptian Psoriasis Patients
title_full_unstemmed	Circulating Cell-Free DNA as Inflammatory Marker in Egyptian Psoriasis Patients
title_sort	circulating cell-free dna as inflammatory marker in egyptian psoriasis patients
publisher	Dove Medical Press
publishDate	2020
url	https://doaj.org/article/f6dcf878d8414c65acd84e901c4972f9
work_keys_str_mv	AT ananihaa circulatingcellfreednaasinflammatorymarkerinegyptianpsoriasispatients AT tawfeikam circulatingcellfreednaasinflammatorymarkerinegyptianpsoriasispatients AT makladss circulatingcellfreednaasinflammatorymarkerinegyptianpsoriasispatients AT kamelam circulatingcellfreednaasinflammatorymarkerinegyptianpsoriasispatients AT elsaidee circulatingcellfreednaasinflammatorymarkerinegyptianpsoriasispatients AT faragas circulatingcellfreednaasinflammatorymarkerinegyptianpsoriasispatients
_version_	1718396980234813440

Circulating Cell-Free DNA as Inflammatory Marker in Egyptian Psoriasis Patients

Ejemplares similares